S 1 (combination)

consists of tegafur, 5-chloro-2,4-dihydroxyuridine & potassium oxonate; an inhibitor of fluorouracil(5-FU) degradation; prolongs the blood 5-FU level as well as increases selective toxicity to tumor; used for the treatment of colon cancer

Also Known As:

Networked: 95 relevant articles (16 outcomes, 50 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kunisaki, Chikara: 7 articles (07/2016 - 07/2008)
2.	Oshima, Takashi: 6 articles (12/2018 - 07/2008)
3.	Takahashi, Masazumi: 6 articles (02/2013 - 07/2008)
4.	Akiyama, Hirotoshi: 5 articles (07/2016 - 07/2008)
5.	Furuse, Junji: 5 articles (03/2015 - 12/2010)
6.	Makino, Hirochika: 5 articles (02/2013 - 07/2008)
7.	Takagawa, Ryo: 5 articles (02/2013 - 07/2008)
8.	Ioka, Tatsuya: 4 articles (02/2019 - 05/2012)
9.	Ishii, Hiroshi: 4 articles (01/2018 - 12/2010)
10.	Kanai, Masashi: 4 articles (12/2016 - 04/2008)

Related Diseases

1.	Stomach Neoplasms (Stomach Cancer) 03/01/2009 - "We conducted this study to evaluate the efficacy of S-1 combination chemotherapy as second-line treatment for advanced/recurrent gastric cancer that was resistant to S-1 based chemotherapy as first-line treatment. " 03/01/2009 - "These results indicate that S-1 combination chemotherapy is efficient as second-line for advanced/recurrent gastric cancer that got resistant to S-1 based chemotherapy as first-line." 05/01/2008 - "PTX and S-1 combination treatment promises good therapeutic efficacy and improves QOL in patients with advanced gastric cancer associated with Schnitzler's metastases." 10/01/2009 - "This case suggests that after failure of S-1 therapy, S-1 combination chemotherapy might be an effective treatment for recurrent gastric cancer." 07/01/2009 - "Docetaxel plus S-1 combination is an active and tolerable regimen as a first-line treatment in patients with advanced or recurrent gastric cancer."
2.	Pancreatic Neoplasms (Pancreatic Cancer) 08/01/2015 - "Mini Abstract: This systematic review analysing randomized controlled trials (RCTs) comparing S-1 combination chemotherapy versus GEM alone for locally advanced and metastatic pancreatic cancer demonstrated greater efficacy for S-1 combination in term of response, disease control and 1-year survival proportion." 01/01/2008 - "The GEM/S-1 combination therapy in patients with pancreatic cancer may be promising and should be tested in clinical trials." 01/01/2008 - "The purpose of this study was to evaluate the relationship between different schedules and the effects of GEM/S-1 combination therapy on pancreatic cancer xenograft models. " 09/01/2015 - "Several reports suggest that gemcitabine (GEM) plus S-1 combination (GS) is associated to prolong the survival in patients with unresectable pancreatic cancer (PC). " 01/01/2018 - "A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged ≥75 years: a study protocol for an open-label randomised feasibility study."
3.	Biliary Tract Neoplasms (Biliary Tract Cancer) 09/01/2010 - "Gemcitabine and S-1 combination chemotherapy is effective and safe in patients with advanced biliary tract cancer." 04/01/2015 - "A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC). " 04/01/2015 - "Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer." 04/01/2013 - "A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer." 01/01/2013 - "The JCOG 0805 study was a randomized Phase II study comparing S-1 monotherapy with gemcitabine plus S-1 combination therapy for unresectable biliary tract cancer. "
4.	Neoplasms (Cancer) 02/01/2011 - "Although the prognosis of patients with unresectable pancreatic acinar cell cancers is generally unfavorable, it is suggested that the GEM/S- 1 combination chemotherapy is effective for these patients' treatment." 09/01/2011 - "Several studies of gemcitabine plus S-1 combination therapy show higher response rates for unresectable tumors. " 11/01/2015 - "After 6 courses of gemcitabine and S-1 combination chemotherapy, the CA19-9 level was normalized and the primary tumor shrank to 79% of its original size. " 05/01/2012 - "Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)."
5.	Neoplasm Metastasis (Metastasis) 01/01/2021 - "A Study on the Effect and Mechanism of Xiaoaiping (XAP) Injection and S-1 Combination Therapy in Inhibiting the Invasion and Metastasis of Human GC Cells." 07/01/2016 - "Survival benefit of S-1 combination therapy over S-1 monotherapy was most pronounced in patients with non-measurable disease, diffuse-type histological features and peritoneal metastasis. " 05/01/2008 - "PTX and S-1 combination treatment promises good therapeutic efficacy and improves QOL in patients with advanced gastric cancer associated with Schnitzler's metastases." 05/01/2014 - "A 43-year-old woman who was diagnosed as having pancreatic cancer with multiple hepatic metastases and duodenal infiltration was administered gemcitabine and S-1 combination therapy. " 01/01/2013 - "[Questions on "gemcitabine plus S-1 combination therapy (G-S therapy) for pancreatic cancer with accentuated hepatic metastasis" (by Matsumoto, T. "

Related Drugs and Biologics

1.	Gemcitabine
2.	Docetaxel (Taxotere)
3.	Cisplatin (Platino)
4.	Paclitaxel (Taxol)
5.	Oxaliplatin (Eloxatin)
6.	Liposomes (Liposome)
7.	Sorafenib (BAY 43-9006)
8.	Irinotecan (Camptosar)
9.	130-nm albumin-bound paclitaxel
10.	Albumin-Bound Paclitaxel

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Neoadjuvant Therapy
4.	Gastrectomy
5.	Combination Drug Therapy (Combination Chemotherapy)